BMJ Open Gastroenterology最新文献

筛选
英文 中文
Toll-like receptor 5 tunes hepatic and pancreatic stellate cells activation. toll样受体5调节肝脏和胰腺星状细胞的激活。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-07-01 DOI: 10.1136/bmjgast-2023-001148
Pietro Di Fazio, Sophia Mielke, Isabell T Böhm, Malte Buchholz, Sami Matrood, Detlef Schuppan, Thaddeus Wissniowski
{"title":"Toll-like receptor 5 tunes hepatic and pancreatic stellate cells activation.","authors":"Pietro Di Fazio,&nbsp;Sophia Mielke,&nbsp;Isabell T Böhm,&nbsp;Malte Buchholz,&nbsp;Sami Matrood,&nbsp;Detlef Schuppan,&nbsp;Thaddeus Wissniowski","doi":"10.1136/bmjgast-2023-001148","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001148","url":null,"abstract":"<p><strong>Objective: </strong>Stellate cells are responsible for liver and pancreas fibrosis and strictly correlate with tumourigenesis. Although their activation is reversible, an exacerbated signalling triggers chronic fibrosis. Toll-like receptors (TLRs) modulate stellate cells transition. TLR5 transduces the signal deriving by the binding to bacterial flagellin from invading mobile bacteria.</p><p><strong>Design: </strong>Human hepatic and pancreatic stellate cells were activated by the administration of transforming growth factor-beta (TGF-β). TLR5 was transiently knocked down by short-interference RNA transfection. Reverse Transcription-quantitativePCR and western blot were performed to analyse the transcript and protein level of TLR5 and the transition players. Fluorescence microscopy was performed to identify these targets in spheroids and in the sections of murine fibrotic liver.</p><p><strong>Results: </strong>TGF-β-activated human hepatic and pancreatic stellate cells showed an increase of <i>TLR5</i> expression. <i>TLR5</i> knockdown blocked the activation of those stellate cells. Furthermore, TLR5 busted during murine liver fibrosis and co-localised with the inducible Collagen I. Flagellin suppressed <i>TLR5</i>, <i>COL1A1</i> and <i>ACTA2</i> expression after the administration of TGF-β. Instead, the antagonist of TLR5 did not block the effect of TGF-β. Wortmannin, a specific AKT inhibitor, induced <i>TLR5</i> but not <i>COL1A1</i> and <i>ACTA2</i> transcript and protein level.</p><p><strong>Conclusion: </strong>TGF-β-mediated activation of hepatic and pancreatic stellate cells requires the over-expression of TLR5. Instead, its autonomous signalling inhibits the activation of the stellate cells, thus prompting a signalling through different regulatory pathways.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/0f/bmjgast-2023-001148.PMC10347502.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9846484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of using a patient education mobile application to improve the quality of bowel preparation: a randomised controlled trial. 使用患者教育移动应用程序提高肠道准备质量的有效性:一项随机对照试验。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001107
Hang Viet Dao, Quan Viet Dao, Hoa Ngoc Lam, Long Bao Hoang, Van Thi Nguyen, Thuy Thi Nguyen, Dat Quoc Vu, Christopher S Pokorny, Hoa Lan Nguyen, Jeroan Allison, Robert Joel Goldberg, An Thi Minh Dao, Toan Thanh Thi Do, Long Van Dao
{"title":"Effectiveness of using a patient education mobile application to improve the quality of bowel preparation: a randomised controlled trial.","authors":"Hang Viet Dao,&nbsp;Quan Viet Dao,&nbsp;Hoa Ngoc Lam,&nbsp;Long Bao Hoang,&nbsp;Van Thi Nguyen,&nbsp;Thuy Thi Nguyen,&nbsp;Dat Quoc Vu,&nbsp;Christopher S Pokorny,&nbsp;Hoa Lan Nguyen,&nbsp;Jeroan Allison,&nbsp;Robert Joel Goldberg,&nbsp;An Thi Minh Dao,&nbsp;Toan Thanh Thi Do,&nbsp;Long Van Dao","doi":"10.1136/bmjgast-2023-001107","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001107","url":null,"abstract":"<p><strong>Aims: </strong>To determine the effectiveness of a mobile application (app) in improving the quality of bowel preparation for colonoscopy.</p><p><strong>Method: </strong>An endoscopist-blinded randomised controlled trial enrolled patients who were undergoing a colonoscopy on the same day of bowel preparation. The intervention used a Vietnamese mobile app that provides instructions on bowel preparation while patients in the comparison group received conventional instructions. Outcomes included the Boston Bowel Preparation Scale (BBPS) to assess the quality of bowel preparation and the polyp detection rate (PDR) and adenoma detection rate (ADR).</p><p><strong>Results: </strong>The study recruited 515 patients (256 in the intervention group). The median age was 42 years, 50.9% were females, 69.1% high school graduates and higher, and 45.2% from urban area. Patients in the intervention group had higher adherence to instructions (60.9% vs 52.4%, p=0.05) and longer length of taking laxatives (mean difference 0.17 hours, 95% CI 0.06 to 0.27). The intervention did not reduce the risk of poor bowel cleansing (total BBPS<6) in both overall (7.4% vs 7.7%; risk ratio 0.96, 95% CI 0.53 to 1.76) and subgroup analysis. PDR and ADR were similar between the two groups.</p><p><strong>Conclusions: </strong>The mobile app providing instructions on proper bowel preparation improved the practice during bowel preparation but did not improve the quality of bowel cleansing or PDR.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/a8/bmjgast-2023-001107.PMC10255132.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EUS-guided through the needle microbiopsy: a useful adjunct in the investigation of pancreatic cystic lesions. eus引导下的针显微活检:胰腺囊性病变的一种有用的辅助检查。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001184
Wafaa Ahmed, Mikaeil Mirzaali, Caroline Young, Latifu Sanni, Simon Everett, Bharat Paranandi, Matthew T Huggett, Wei On
{"title":"EUS-guided through the needle microbiopsy: a useful adjunct in the investigation of pancreatic cystic lesions.","authors":"Wafaa Ahmed,&nbsp;Mikaeil Mirzaali,&nbsp;Caroline Young,&nbsp;Latifu Sanni,&nbsp;Simon Everett,&nbsp;Bharat Paranandi,&nbsp;Matthew T Huggett,&nbsp;Wei On","doi":"10.1136/bmjgast-2023-001184","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001184","url":null,"abstract":"<p><strong>Objective: </strong>Endoscopic ultrasound-guided through-the-needle microbiopsy (EUS-TTNB) forceps is a recent development that facilitates sampling of the walls of pancreatic cystic lesions (PCL) for histological analysis. We aimed to assess the impact of EUS-TTNB and its influence on patient management in a tertiary pancreas centre.</p><p><strong>Design: </strong>A prospective database of consecutive patients who underwent EUS-TTNB from March 2020 to August 2022 at a tertiary referral centre was retrospectively analysed.</p><p><strong>Results: </strong>Thirty-four patients (22 women) were identified. Technical success was achieved in all cases. Adequate specimens for histological diagnosis were obtained in 25 (74%) cases. Overall, EUS-TTNB led to a change in management in 24 (71%) cases. Sixteen (47%) patients were downstaged, with 5 (15%) discharged from surveillance. Eight (24%) were upstaged, with 5 (15%) referred for surgical resection. In the 10 (29%) cases without change in management, 7 (21%) had confirmation of diagnosis with no change in surveillance, and 3 (9%) had insufficient biopsies on EUS-TTNB. Two (6%) patients developed post-procedural pancreatitis, and 1 (3%) developed peri-procedural intracystic bleeding with no subsequent clinical sequelae.</p><p><strong>Conclusion: </strong>EUS-TTNB permits histological confirmation of the nature of PCL, which can alter management outcomes. Care should be taken in patient selection and appropriately consented due to the adverse event rate.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/b6/bmjgast-2023-001184.PMC10314575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review. 非药物干预改善患者结肠镜检查结果的随机对照试验:范围回顾。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001129
Colin Sue-Chue-Lam, Matthew Castelo, Amina Benmessaoud, Teruko Kishibe, Diego Llovet, Christine Brezden-Masley, Amy Yx Yu, Jill Tinmouth, Nancy N Baxter
{"title":"Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review.","authors":"Colin Sue-Chue-Lam,&nbsp;Matthew Castelo,&nbsp;Amina Benmessaoud,&nbsp;Teruko Kishibe,&nbsp;Diego Llovet,&nbsp;Christine Brezden-Masley,&nbsp;Amy Yx Yu,&nbsp;Jill Tinmouth,&nbsp;Nancy N Baxter","doi":"10.1136/bmjgast-2023-001129","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001129","url":null,"abstract":"<p><strong>Background and aims: </strong>Non-pharmacological interventions to improve patient-reported outcomes of colonoscopy may be effective at mitigating negative experiences and perceptions of the procedure, but research to characterise the extent and features of studies of these interventions is limited.</p><p><strong>Methods: </strong>We conducted a scoping review searching multiple databases for peer-reviewed publications of randomised controlled trials conducted in adults investigating a non-pharmacological intervention to improve patient-reported outcomes of colonoscopy. Study characteristics were tabulated and summarised narratively and graphically.</p><p><strong>Results: </strong>We screened 5939 citations and 962 full texts, and included 245 publications from 39 countries published between 1992 and 2022. Of these, 80.8% were full publications and 19.2% were abstracts. Of the 41.9% of studies reporting funding sources, 11.4% were unfunded. The most common interventions were carbon dioxide and/or water insufflation methods (33.9%), complementary and alternative medicines (eg, acupuncture) (20.0%), and colonoscope technology (eg, magnetic scope guide) (21.6%). Pain was as an outcome across 82.0% of studies. Studies most often used a patient-reported outcome examining patient experience during the procedure (60.0%), but 42.9% of studies included an outcome without specifying the time that the patient experienced the outcome. Most intraprocedural patient-reported outcomes were measured retrospectively rather than contemporaneously, although studies varied in terms of when outcomes were assessed.</p><p><strong>Conclusion: </strong>Research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy is unevenly distributed across types of intervention and features high variation in study design and reporting, in particular around outcomes. Future research efforts into non-pharmacological interventions to improve patient-reported outcomes of colonoscopy should be directed at underinvestigated interventions and developing consensus-based guidelines for study design, with particular attention to how and when outcomes are experienced and measured.</p><p><strong>Prospero registration number: </strong>42020173906.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/03/bmjgast-2023-001129.PMC10255139.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease. 炎症性肠病患者6-硫鸟嘌呤核苷酸水平与预防英夫利昔单抗抗体产生之间的关系
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-06-01 DOI: 10.1136/bmjgast-2023-001149
Jennifer Phillips, Sam Leary, Jonathan Tyrrell-Price
{"title":"Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease.","authors":"Jennifer Phillips, Sam Leary, Jonathan Tyrrell-Price","doi":"10.1136/bmjgast-2023-001149","DOIUrl":"10.1136/bmjgast-2023-001149","url":null,"abstract":"<p><strong>Objective: </strong>Combination therapy with infliximab and a thiopurine has been shown to be more effective than monotherapy in patients with inflammatory bowel disease (IBD). The therapeutic efficacy of thiopurines is correlated with 6-thioguanine (6-TGN) levels between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes. The primary aim of the study was to investigate the association between 6-TGN levels and inhibition prevention of the production of antibodies to infliximab (ATI).</p><p><strong>Design: </strong>We performed a retrospective review of the medical records of patients being treated with infliximab for IBD at University Hospitals Bristol NHS Foundation Trust. Demographic and biochemical data were extracted, alongside thiopurine metabolite levels, trough levels of infliximab and the presence of ATI. χ<sup>2</sup> tests were used to investigate the association between 6-TGN levels and prevention of ATI. Logistic regression was used to compare the odds of prevented ATI between those with a 6-TGN level between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes, those with a 6-TGN level outside of this range, and the baseline group who were on infliximab monotherapy.</p><p><strong>Results: </strong>Data were extracted for 100 patients. Six of 32 patients with a 6-TGN level between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes developed ATI (18.8%) compared with 14 out of 22 (63.6%) patients with a 6-TGN outside of this range and 32 out of 46 (69.6%) patients on monotherapy (p=0.001). The OR (95% CI) for prevented ATI in those with a 6-TGN between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes compared with a 6-TGN outside of this range was 7.6 (2.2, 26.3) (p=0.001) and compared with monotherapy was 9.9 (3.3, 29.4) (p=0.001).</p><p><strong>Conclusion: </strong>6-TGN levels between 235 and 450 pmol/8×10<sup>8</sup> erythrocytes prevented production of ATI. This supports therapeutic drug monitoring to help guide treatment and maximise the beneficial effects of combination therapy for patients with IBD.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/3e/bmjgast-2023-001149.PMC10277032.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Planning management for complex colorectal polyps: a qualitative assessment of factors influencing decision-making among colonoscopists. 复杂结肠息肉的计划管理:影响结肠镜医师决策因素的定性评估。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2022-001097
Jody Parker, Lenira Semedo, Lavanya Shenbagaraj, Jared Torkington, Sunil Dolwani
{"title":"Planning management for complex colorectal polyps: a qualitative assessment of factors influencing decision-making among colonoscopists.","authors":"Jody Parker,&nbsp;Lenira Semedo,&nbsp;Lavanya Shenbagaraj,&nbsp;Jared Torkington,&nbsp;Sunil Dolwani","doi":"10.1136/bmjgast-2022-001097","DOIUrl":"https://doi.org/10.1136/bmjgast-2022-001097","url":null,"abstract":"<p><strong>Objective: </strong>Endoscopic therapy is the recommended primary treatment for most complex colorectal polyps, but high colonic resection rates are reported. The aim of this qualitative study was to understand and compare between specialities, the clinical and non-clinical factors influencing decision making when planning management.</p><p><strong>Design: </strong>Semi-structured interviews were performed among colonoscopists across the UK. Interviews were conducted virtually and transcribed verbatim. Complex polyps were defined as lesions requiring further management planning rather than those treatable at the time of endoscopy. A thematic analysis was performed. Findings were coded to identify themes and reported narratively.</p><p><strong>Results: </strong>Twenty colonoscopists were interviewed. Four major themes were identified including gathering information regarding the patient and their polyp, aids to decision making, barriers in achieving optimal management and improving services. Participants advocated endoscopic management where possible. Factors such as younger age, suspicion of malignancy, right colon or difficult polyp location lead towards surgical intervention and were similar between surgical and medical specialties. Availability of expertise, timely endoscopy and challenges in referral pathways were reported barriers to optimal management. Experiences of team decision-making strategies were positive and advocated in improving complex polyp management. Recommendations based on these findings to improve complex polyp management are provided.</p><p><strong>Conclusion: </strong>The increasing recognition of complex colorectal polyps requires consistency in decision making and access to a full range of treatment options. Colonoscopists advocated the availability of clinical expertise, timely treatment and education in avoiding surgical intervention and providing good patient outcomes. Team decision-making strategies for complex polyps may provide an opportunity to coordinate and improve these issues.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/2a/bmjgast-2022-001097.PMC10230910.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstacles to the deceased donor transplantation in Pakistan. 巴基斯坦死亡供体移植的障碍。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2022-001101
Kaleem Ullah, Abdul Wahab Dogar, Sidhant Ochani, Azam Shoaib, Hussain Haider Shah, Mohammad Ebad Ur Rehman
{"title":"Obstacles to the deceased donor transplantation in Pakistan.","authors":"Kaleem Ullah,&nbsp;Abdul Wahab Dogar,&nbsp;Sidhant Ochani,&nbsp;Azam Shoaib,&nbsp;Hussain Haider Shah,&nbsp;Mohammad Ebad Ur Rehman","doi":"10.1136/bmjgast-2022-001101","DOIUrl":"https://doi.org/10.1136/bmjgast-2022-001101","url":null,"abstract":"<p><strong>Introduction: </strong>Transplantation in many Asian countries is moulded by socioeconomic, religious, cultural and health indicators. In most Asian countries, the living-related donation is the common most organ donation. Due to the limited deceased organ donation, live donor programmes flourished in many Asian countries. Another apparent reason for this tremendous growth of living-related programmes in Asian countries is their larger serving population. Several centres from Asia, including Pakistan and India from Southeast Asia and Egypt in Middle East Asia, on the one hand, have recently emerged as leading living donor transplant programmes. On the other hand, a few Asian countries, including Iran and China, have established some of the world's largest deceased donor programmes.</p><p><strong>Discussion: </strong>In Pakistan, thousands of patients die from end-stage organ failure annually, seeking organ transplants for survival. The exact statics are not available, but over 50 000 people are estimated to die each year as a result of end-stage organ failure without getting a transplant, about 15 000-18 000 from kidney failure, and 10 000 from liver failure and the National Centre for Health Statistics labelled organ failure as a leading cause of death. Despite all these efforts, the knowledge of organ donation among Pakistani people was determined to be around 60%. In Pakistan, the lack of deceased organ donation programmes and the unwillingness of people to deceased organ donation contributes to an increased demand for living organ donation and patients continue to rely on living donors. We discuss various obstacles to deceased organ donation comprising various challenges that form a unique combination, including religious, economic, social, demographic and political factors.<b>Conclusion:</b> Every single effort should be made to initiate and establish multiple deceased donor programmes in Pakistan. Developing the deceased donor programmes in the country will be vital to counter the countrywide increasing organ shortage. The mainstay transplant activities like organ procurement and distribution systems need to be adequately developed. It will help achieve national self-sufficiency and decrease living donors' burden. With education, the behaviour of healthcare professionals and common people can be changed and a positive attitude toward deceased organ donation can be obtained. As healthcare professionals, we should come forward and take responsibility by enrolling ourselves in deceased donors' registration. Public awareness, medical community interest and government support are essential in initiating and establishing deceased donor programmes in Pakistan.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/01/bmjgast-2022-001101.PMC10230924.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe SARS-CoV-2 infection: does the artificial sweetener sucralose play a role? 严重的SARS-CoV-2感染:人工甜味剂三氯蔗糖起作用吗?
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2023-001159
Susan S Schiffman, H Troy Nagle
{"title":"Severe SARS-CoV-2 infection: does the artificial sweetener sucralose play a role?","authors":"Susan S Schiffman,&nbsp;H Troy Nagle","doi":"10.1136/bmjgast-2023-001159","DOIUrl":"https://doi.org/10.1136/bmjgast-2023-001159","url":null,"abstract":"","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/b4/bmjgast-2023-001159.PMC10186079.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9473872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. 炎症性肠病患者罹患恶性淋巴瘤的风险:一项基于人群的队列研究。
IF 3.3
BMJ Open Gastroenterology Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2022-001037
Jingru Yu, Erle Refsum, Paulina Wieszczy, Lise M Helsingen, Vera Perrin, Amanda Högdén, Magnus Løberg, Johannes Blom, Michael Bretthauer, Hans-Olov Adami, Weimin Ye, Mette Kalager
{"title":"Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study.","authors":"Jingru Yu, Erle Refsum, Paulina Wieszczy, Lise M Helsingen, Vera Perrin, Amanda Högdén, Magnus Løberg, Johannes Blom, Michael Bretthauer, Hans-Olov Adami, Weimin Ye, Mette Kalager","doi":"10.1136/bmjgast-2022-001037","DOIUrl":"10.1136/bmjgast-2022-001037","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the risk of non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) in patients with inflammatory bowel disease (IBD).</p><p><strong>Design: </strong>We undertook a two-country population cohort study with all patients diagnosed with IBD in Norway and Sweden from 1987 and 1993 through 2015 and 2016, respectively, and analysed the risk of NHL and HL. In Sweden, we also analysed prescriptions of thiopurines and anti-tumour necrosis factor (TNF)-α therapy from 2005. We calculated standardised incidence ratios (SIRs) with 95% CIs using the general populations as reference.</p><p><strong>Results: </strong>Among 131 492 patients with IBD with a medium follow-up of 9.6 years, we identified 369 cases of NHL and 44 cases of HL. The SIR of NHL was 1.3 (95% CI 1.1 to 1.5) in ulcerative colitis and 1.4 (95% CI 1.2 to 1.7) in Crohn's disease. We found no compelling heterogeneity in analyses stratified by patient characteristics. We found a similar pattern and magnitude of excess risks for HL. At 10 years, cumulative incidence was 0.26% (95% CI 0.23% to 0.30%) and 0.06% (95% CI 0.04% to 0.08%) for NHL and HL, respectively. Higher excess risks were found among patients with NHL with concomitant primary sclerosing cholangitis (SIR 3.4; 95% CI 2.1 to 5.2) and in those prescribed thiopurines alone (SIR 2.8; 95% CI 1.4 to 5.7) or with anti-TNF-α agents (SIR 5.7; 95% CI 2.7 to 11.9).</p><p><strong>Conclusion: </strong>Patients with IBD have a statistically significant increased risk of malignant lymphomas compared with the general population, but the absolute risk remains low.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/01/bmjgast-2022-001037.PMC10163486.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dutch individuals' views of screening for oesophageal cancer: a focus group study. 荷兰个体对癌症筛查的看法:一项焦点小组研究。
IF 3.1
BMJ Open Gastroenterology Pub Date : 2023-05-01 DOI: 10.1136/bmjgast-2023-001136
Jasmijn Sijben, Yonne Peters, Sharell Bas, Peter Siersema, Linda Rainey, Mireille Broeders
{"title":"Dutch individuals' views of screening for oesophageal cancer: a focus group study.","authors":"Jasmijn Sijben,&nbsp;Yonne Peters,&nbsp;Sharell Bas,&nbsp;Peter Siersema,&nbsp;Linda Rainey,&nbsp;Mireille Broeders","doi":"10.1136/bmjgast-2023-001136","DOIUrl":"10.1136/bmjgast-2023-001136","url":null,"abstract":"<p><strong>Objective: </strong>Screening for early oesophageal adenocarcinoma (OAC), including its precursor Barrett's oesophagus (BO), can potentially reduce OAC-related morbidity and mortality. This study explores Dutch at-risk individuals' views of screening an at-risk population for BO/OAC.</p><p><strong>Design: </strong>We invited 372 individuals with risk factors for OAC from primary care practices, 73 individuals with surveillance experience, and 221 participants of previous studies (BO/OAC screening trial or survey) to participate in focus groups. Transcripts were inductively and thematically analysed by two independent researchers.</p><p><strong>Results: </strong>A total of 50 individuals (42% with gastro-oesophageal reflux symptoms) of 50-75 years participated. Themes that were raised included: theme 1 'screening intentions' describing participants' motivation to be screened (eg, early diagnosis, potential reassurance, physician recommendation, and knowing someone with cancer) or decline screening (eg, anticipated discomfort or suboptimal accuracy of the test); theme 2 'risk-based eligibility' describing the tension between effectiveness (eg, targeting high-risk individuals) and inclusivity (eg, making screening available for everyone); theme 3 'distributive justice', in which the pressure of a potential new screening programme on healthcare resources was discussed; and theme 4 'information needs' describing the perceived lack of information access and individuals' preference to discuss screening with their general practitioner.</p><p><strong>Conclusion: </strong>Individuals not only expressed high willingness to be screened but also voiced the concern that a new screening programme may pressure limited healthcare resources. If implemented, it is crucial to develop educational materials that meet the public's information needs and explain the test procedures and eligibility criteria while avoiding stigmatising language.</p>","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10350905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信